Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Savient Pharmaceuticals Inc (formerly Bio-Technology General Corp), under license from Duke University, is developing pegloticase, PEG conjugates of uricase (urate oxidase), for the potential treatment of gout. The in-life portion of the phase III trials have been completed.
Biggers
Kristen
K
West Virginia University School of Medicine, Robert C Byrd Health Sciences Center, Morgantown, WV 26506-9100, USA.
Scheinfeld
Noah
N
D000818:Animals; D003692:Delayed-Action Preparations; D004353:Drug Evaluation, Preclinical; D006073:Gout / Q000188:drug therapy*; D006074:Gout Suppressants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D015394:Molecular Structure; D010330:Patents as Topic; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D016896:Treatment Outcome; D014503:Urate Oxidase / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D006074:Gout Suppressants; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D014503:Urate Oxidase; C031545:Pegloticase